Medicine
Procardia XL 30 mg extended-release tablet
Procardia XL 30 mg extended-release tablet is a prescription medicine containing Nifedipine for oral use, marketed by Pfizer Laboratories, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store below 86°F (30°C). Protect from moisture and humidity.
Key facts
- Active ingredient (INN)
- Nifedipine
- Brand
- Procardia XL
- Strength
- 30 mg
- Dosage form
- Extended-release tablet
- Route
- Oral
- Packs
- 100 tablets, 300 tablets
- Marketing authorisation holder
- Pfizer Laboratories
- Manufacturer
- Pfizer Laboratories
- Origin register
- US FDA, United States
- Storage
- Store below 86°F (30°C). Protect from moisture and humidity.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- C08CA05 Nifedipine
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 6 September 1989
- Identifiers
- RxCUI 207772, 207773, 1812011 +1DailyMed set ID 8ebcb33c-f43b-4b36-9f94-9774b2a59e06NDC 0069-2650Application NDA019684
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 100 tablet, film coated, extended release in 1 blister pack | 0069-2650-41 | Pfizer Laboratories | 6 September 1989 |
| 100 tablet, film coated, extended release in 1 bottle | 0069-2650-66 | Pfizer Laboratories | 6 September 1989 |
| 300 tablet, film coated, extended release in 1 bottle | 0069-2650-72 | Pfizer Laboratories | 6 September 1989 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 31 December 1981 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Nifedipine 30 mg extended-release tablet.
Other strengths and forms of Nifedipine
Clinical summary
Nifedipine is a dihydropyridine calcium channel blocker indicated for the management of vasospastic angina confirmed by any of criteria, among other approved uses. It is available as extended-release tablets and capsules for oral use. MedsAcross supplies Nifedipine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about NifedipineFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Procardia XL prescribing information (Pfizer Laboratories) · U.S. National Library of Medicine, DailyMed
Need Procardia XL 30 mg extended-release tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.